不含麩質 - 本產品不含可檢測出之麩質*

不含可檢測出之基改成份(GMO) - 本產品不含可檢測出之基因改造生物成份

等滲壓營養補充沖飲 - 易於飲用的營養補充品 / 健康食品，透過等滲壓狀態達致更佳的營養吸收

品質標準 - 良好生產規範(GMP)運作與標準化成份

已檢測：重金屬丶微生物污染物丶過敏原丶效力丶純度及特性

*美國食品藥品監督管理局（FDA）將含有少於20PPM麩質的製成產品列為不含麩質

葡萄糖胺
葡萄糖胺是人體利用葡萄糖和氨基酸麩醯胺酸自然合成的分子。葡萄糖胺是組成軟骨基質和關節液中黏多醣的重要成分。隨著人體老化，我們製造葡萄糖胺的能力會下降，令軟骨變得脆弱，靈活性減低。雖然確實機制未明，但研究顯示，補充葡萄糖胺可支援製造正常、健康的軟骨細胞，以支援整體關節健康。

松樹皮萃取物（碧容健®）
碧容健是具有強效益處的水溶性類黃酮複合物。碧容健與葡萄籽內的原花青素相似，同樣由法國海岸松樹皮提取而成。
研究顯示，碧容健有助維持人體的天然防禦能力，支援良好健康。此外，研究亦顯示碧容健可支援膠原蛋白纖維和其他結締組織之間的交聯。

玻尿酸
玻尿酸對維持組織水分和潤滑度非常重要。雖然人體可自然製造玻尿酸，但玻尿酸水平會隨年齡增長而減少，造成關節不適。玻尿酸是組成軟骨的重要成分，對關節健康非常重要。研究顯示，玻尿酸有助維持軟骨強健，並促進關節液的製造。

甚麼人適合飲用Prime Isotonix 健絡關節沖飲？
此產品只適合成人使用。任何希望支援和維持關節健康的成人均可使用此產品。

Prime Isotonix 健絡關節沖飲應配合甚麼產品使用，以支援關節健康？
Heart Health™魚油與 Prime Isotonix 健絡關節沖飲是很好的配搭，因為魚油中的奧米加 3 脂肪酸獲證實可支援健康的潤滑關節功能。

如何飲用Prime Isotonix 健絡關節沖飲？
將兩小瓶蓋（白色螺旋蓋）的粉末倒入杯中，加入 120 毫升水，攪拌後飲用。本品為健康食品，每天飲用一次或按醫護人員指示飲用。空肚飲用時效果最佳。使用規定量的粉劑與水混合才會使本產品達到等滲狀態。

Prime Isotonix 健絡關節沖飲含有多少碧容健®？
每天食用份量含有 25 毫克碧容健。

飲用Prime Isotonix 健絡關節沖飲安全嗎？
Prime Isotonix 健絡關節沖飲安全及不含有害物質。本品在美國製造，並於經美國食品及藥物管理局檢測的設備生產，符合良好生產規範。顧客對本產品的質量和安全可絕對有信心。

• Belcaro, G., et al. Variations in C-reactive protein, plasma free radicals and fibrinogen values in patients with osteoarthritis treated with Pycnogenol®. Redox Report. 13(6): 271-276, 2008.
• Blewis, M., et al. A model of synovial fluid lubricant composition in normal and injured joints. European Cells and Materials. 13: 26-39, 2007.
• Braham, R., et al. The effect of glucosamine supplementation on people experiencing regular knee pain. British Journal of Sports Medicine. 37(1): 45-49, 2003.
• Canali, R., et al. The anti-inflammatory pharmacology of Pycnogenol® in humans involves COX-2 and 5-LOX mRNA expression in leukocytes. International Immunopharmacology. 9(10): 1145-1149, 2009.
• Chang, X., et al. Inhibition of antithrombin by hyaluronic acid may be involved in the pathogenesis of rheumatoid arthritis. Arthritis Research and Therapy. 7(2): R268-R273, 2005.
• Chou, M., et al. Effects of chondroitin and glucosamine sulfate in a dietary bar formulation on inflammation, interleukin-1beta, matrix metalloprotease-9, and cartilage damage in arthritis. Experimental Biology and Medicine. 230(4): 255-262, 2005.
• Cisár, P., et al. Effect of pine bark extract (Pycnogenol®) on symptoms of knee osteoarthritis. Phytotherapy Research. 22: 1087-1092, 2008.
• Elliott, A., et al. Serum hyaluronan levels and radiographic knee and hip osteoarthritis in African Americans and Caucasians in the Johnston County Osteoarthritis Project. Arthritis and Rheumatism. 52(1): 105-111, 2005.
• Farid, R., et al. Pycnogenol® supplementation reduces pain and stiffness and improves physical function in adults with knee osteoarthritis. Nutrition Research. 27: 692-697, 2007.
• Gaby, A. Natural treatments for osteoarthritis. Alternative Medicine Review. 4(5): 330-341, 1999.
• Gouze, J., et al. Exogenous glucosamine globally protects chondrocytes from the arthritogenic effects of IL-1beta. Arthritis Research and Therapy. 8(6): R173
• Grimm, T., et al. Inhibition of NF-kappaB activation and MMP-9 secretion by plasma of human volunteers after ingestion of maritime pine bark extract (Pycnogenol®). Journal of Inflammation. 3: 1-15, 2006.
• Hua, J., et al. Inhibitory actions of glucosamine, a therapeutic agent for osteoarthritis, on the functions of neutrophils. Journal of Leukocyte Biology. 71(4): 632-640, 2002.
• James, C. and Uhl, T. A review of articular cartilage pathology and the use of glucosamine sulfate. Journal of Athletic Training. 36(4): 413-419, 2001.
• Julovi, S., et al. Inhibition of interleukin-1beta-stimulated production of matrix metalloproteinases by hyaluronan via CD44 in human articular cartilage. Arthritis and Rheumatism. 50(2): 516-525, 2004.
• Laurent, T., et al. Functions of hyaluronan. Annals of the Rheumatic Disease. 54(5): 429-432, 1995.
• Kelly, G. The role of glucosamine sulfate and chondroitin sulfates in the treatment of degenerative joint disease. Alternative Medicine Review. 3(1): 27-39, 1998.
• McDonald, J. and Levick, J. Hyaluronan reduces fluid escape rate from rabbit knee joints disparately from its effect on fluidity. Experimental Physiology. 79(1): 103-106, 1994.
• Nakatani, S., et al. Glucosamine regulates differentiation of a chondrogenic cell line, ATDC5. Biological and Pharmaceutical Bulletin. 30(3): 433-438, 2007.
• Ohno, S., et al. Hyaluronan oligosaccharides induce matrix metalloproteinase 13 via transcriptional activation of NFkappaB and p38 MAP kinase in articular chondrocytes. Journal of Biological Chemistry. 281(26): 17952-17960, 2006.
• Poustie, M., et al. N-butyryl glucosamine increases matrix gene expression by chondrocytes. Journal of Pharmacology and Experimental Therapeutics. 311(2): 610-616, 2004.
• Reginster, J., et al. Current concepts in the therapeutic management of osteoarthritis with glucosamine. Bulletin (Hospital for Joint Disease). 63(1-2): 31-36, 2005.
• Reginster, J., et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomized, placebo-controlled clinical trial. Lancet. 357(9252): 251-256, 2001.
• Richy, F., et al. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Archives of Internal Medicine. 163(13): 1514-1522, 2003.
• Santangelo, K., et al. Effects of hyaluronan treatment on lipopolysaccharide-challenged fibroblast-like synovial cells. Arthritis Research and Therapy. 9(1): R1, 2007.
• Sasaki, A., et al. Hyaluronate inhibits the interleukin-1beta-induced expression of matrix metalloproteinase (MMP)-1 and MMP-3 in human synovial cells. The Tohoku Journal of Experimental Medicine. 204(2): 99-107, 2004.
• Schäfer, A., et al. Inhibition of COX-1 and COX-2 activity by plasma of human volunteers after ingestion of French maritime pine bark extract (Pycnogenol®). Biomedicine and Pharmacotherapy. 60: 5-9, 2006.